June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Long-Term Safety and Efficacy of Intraoperative Triamcinolone-Moxifloxacin Injection versus Postoperative Drops for Infectious and Inflammatory Prophylaxis after Cataract Surgery
Author Affiliations & Notes
  • Rishi Singhal
    Penn State Eye Center, Duluth, Georgia, United States
  • Andrew Luo
    Penn State Eye Center, Duluth, Georgia, United States
  • Tara O'Rourke
    Penn State Eye Center, Duluth, Georgia, United States
  • Ingrid U Scott
    Penn State Eye Center, Duluth, Georgia, United States
  • Seth Pantanelli
    Penn State Eye Center, Duluth, Georgia, United States
  • Footnotes
    Commercial Relationships   Rishi Singhal, None; Andrew Luo, None; Tara O'Rourke, None; Ingrid Scott, None; Seth Pantanelli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1687. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rishi Singhal, Andrew Luo, Tara O'Rourke, Ingrid U Scott, Seth Pantanelli; Long-Term Safety and Efficacy of Intraoperative Triamcinolone-Moxifloxacin Injection versus Postoperative Drops for Infectious and Inflammatory Prophylaxis after Cataract Surgery. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1687.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the safety and efficacy of intraoperative triamcinolone-moxifloxacin (Imprimis’ Tri-Moxi 15mg/1mg/mL) injection versus postoperative polymyxin b/trimethoprim and prednisolone acetate 1% eye drops for infectious and inflammatory prophylaxis during the two-year postoperative period following phacoemulsification cataract surgery.

Methods : From January through October 2017, patients undergoing cataract surgery by a single surgeon at Penn State Eye Center were offered a single intraoperative injection of transzonular triamcinolone-moxifloxacin in lieu of postoperative eye drops. From November 2017 through July 2018, this injection was not offered, and all patients were prescribed a postoperative regimen of polymyxin b/trimethoprim and prednisolone acetate 1%. A retrospective chart review was performed to record evidence of infectious sequelae, symptomatic uveitis, and elevated intraocular pressure (IOP) which occurred >10 weeks postoperatively.

Results : Of the 198 eyes, 99 from 73 patients received the injection and 99 from 82 patients received topical drops. Follow-up for eyes in the injection group (25.0 months) was longer than in the drop group (16.2 months; p<0.0001). No patients experienced infectious sequelae in either group. All patients who developed rebound inflammation (defined as at least 1+ anterior chamber reaction with subjective patient complaints before postoperative week 10 [11 eyes in the injection group and 3 eyes in the drop group]) resolved with treatment without further episodes of intraocular inflammation. The mean IOP in the injection (14.6 mmHg) and drop (14.4 mmHg) groups were similar (p = 0.67). No patients had IOP above 23 mmHg in either group.

Conclusions : Although triamcinolone-moxifloxacin was previously shown to be associated with higher rates of rebound inflammation relative to the topical drop regimen, long-term analyses suggest both groups of patients have similar outcomes with respect to uveitic sequelae, infectious complications, and elevated IOP.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×